APA (7th ed.) Citation

M, C., CP, P., & MG, M. (2026). IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities. Lung, 204(1), . https://doi.org/10.1007/s00408-026-00897-9

Chicago Style (17th ed.) Citation

M, Cazzola, Page CP, and Matera MG. "IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities." Lung 204, no. 1 (2026). https://doi.org/10.1007/s00408-026-00897-9.

MLA (9th ed.) Citation

M, Cazzola, et al. "IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities." Lung, vol. 204, no. 1, 2026, https://doi.org/10.1007/s00408-026-00897-9.